Efficacy of an algorithm-guided treatment compared with treatment as usual: A randomized, controlled study of inpatients with depression

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 327-333

  Bauer, Michael ^a   Pfennig, Andrea ^a   Linden, Michael ^b   Smolka, Michael N ^a   Neu, Peter ^c   Adli, Mazda ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Rehabilitation Centre Seehof   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Algorithm; Depression; Outcome; Treatment as usual

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; HALOPERIDOL; HYPNOTIC AGENT; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; TRANYLCYPROMINE; VENLAFAXINE;

ADULT; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; ELECTROCONVULSIVE THERAPY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS; SLEEP DEPRIVATION; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTIDEPRESSIVE AGENTS; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DEPRESSION; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; FEASIBILITY STUDIES; FEMALE; GERMANY; HUMANS; INPATIENTS; LITHIUM CARBONATE; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PATIENT DROPOUTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SLEEP DEPRIVATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68449098784     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ac4839     Document Type: Article

References (35)

1. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914-919.
2. Nolen WA, Haffrnans J. Treatment of resistant depression. Review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants. Int Clin Psychopharmacol. 1989;4:217-228.
3. AHCPR (Agency for Health Care Policy and Research). Evidence Report on Treatment of Depression: Newer Pharmacotherapies. Washington, DC: San Antonio Evidence-Based Practice Center; 1999.
4. Keller MB. Issues in treatment-resistant depression. J Clin Psychiatry. 2005;66(suppl 8):5-12.
5. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:5-43.
6. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3:69-86.
7. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
8. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.
9. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081-1097.
10. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007;52:46-54.
11. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:243-261.
12. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am. 1996;19:371-386.
13. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry. 1998;59:345-351.
14. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry. 1998; 59(suppl 20):73-84.
15. Linden M, Helmchen H, Mackert A, et al. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed inpatients. Pharmacopsychiatry. 1994;27(suppl 1):51-53.
16. Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry. 2006;59:1029-1038.
17. Adli M, Berghofer A, Linden M, et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry. 2002;63:782-790.
18. Adli M, Rush AJ, Moller HJ, et al. Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry. 2003;36(suppl 3):S222-S229.
19. World Health Organization. International Classification of Diseases, 10th Revision. Geneva, Switzerland: WHO; 1996.
20. WHO. Composite International Diagnostic Interview - Version 1.1. Geneva, Switzerland: WHO; 1993.
21. Bech P, Rafaelsen OJ. The melancholia scale: development, consistency, validity and utility. In: Sartorius N, Ban TA, eds. Assessment of Depression. Berlin, Germany: Springer; 1986:259-269.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
23. Maier W, Philipp M, Heuser I, et al. Improving depression severity assessment-I. Reliability, internal validity and sensitivity to change of three observer depression scales. J Psychiatr Res. 1988;22:3-12.
24. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry. 2004;61:669-680.
25. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
26. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
27. Birkenhager TK, van den Broek WW, Moleman P, et al. Outcome of a 4-step treatment algorithm for depressed inpatients. J Clin Psychiatry. 2006;67:1266-1271.
28. Zerssen von D. Klinische Selbstbeurteilungsskalen aus dem Münchner Psychiatrischen Informations-System, a) Die Beschwerden-Liste. b) Die Depressivitätsskala. Weinheim, Germany: Beltz; 1976.
29. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry. 1996;29:87-96.
30. Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64:413-420.
31. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
32. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized placebo-controlled trials. J Clin Psychiatry. 2007;68:935-940.
33. Birkenhager TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004;65:1505-1510.
34. Nolen WA, van den Broek WW, Birkenhager TK. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. Am J Psychiatry. 2007;164:524.
35. Adli M, Pilhatsch M, Bauer M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry. 2008;41:252-257.